Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,901–3,000 of 4,628
Pulmonary Hypertension due to Fibrotic Lung Disease: Hidden Value in a Neutral Trial
Nathan, S. D., & Carbone, R. G. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1094ed · Cited by 5
Maldonado, F., & Kropski, J. A. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.331 · Cited by 5
Solomon, J. J., Danoff, S. K., Woodhead, F., et al. (2022) · medRxiv · doi:10.1101/2022.04.01.22273270 · Cited by 5
Self-citationMaher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4
A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity
Zhan, J. J., Jarrell, Z. R., Hu, X., Weinberg, J., Orr, M. L., Marts, L. T., Jones, D. P., & Go, Y. (2024) · Physiological Reports · doi:10.14814/phy2.70093 · Cited by 4
“In line with this, the application of a tyrosine kinase inhibitor, “Nintedanib” mitigated the progression of IPF in phase 3 clinical trials and received the U.S. Food and Drug Administration approval as the first treatment for patients with progressive fibrosing ILD (Richeldi et al., 2014).”
BackgroundMatics, Z., Bardóczi, A. B., Galkó, C., Szabó, B., Gede, N., Molnár, Z., Duray, G. Z., Turan, C., Hegyi, P., Horváth, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102966 · Cited by 4
Aneurysm Is Restricted by CD34+ Cell‐Formed Fibrous Collars Through the PDGFRb‐PI3K Axis
Wu, H., Yang, X., Chen, T., Yu, B., Chen, M., Wang, T. Z., Jiang, L., Zhang, B., Zhou, X., Cheng, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202408996 · Cited by 12
Petrarulo, S., Ravaglia, C., White, S., Madsen, L. B., Lex, F., Dubini, A., Fabbri, E., Bendstrup, E. M., Spagnolo, P., Piciucchi, S., et al. (2024) · Pulmonology · doi:10.1080/25310429.2024.2425503 · Cited by 6
Pericytes in the Pulmonary Microenvironment: Guardians or Adversaries?
Lin, Y., Chen, J., Tan, J.-L., Yu, Z., Pi, R., Xiong, J., Ding, Y., Chen, M., & Bai, X. (2025) · Lung · doi:10.1007/s00408-025-00820-8 · Cited by 4
Zheng, L., Xinyu, A., Ma, S., Xu, B., Xiang, Z., Cao, B., Shen, J., Xu, X., Cheng, Y., Ran, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1696932 · Cited by 6
Chitosan Nanoparticles for Pulmonary Delivery of Curcumin/Nintedanib to Treat Pulmonary Fibrosis
Jin, M., Liu, J., Shao, M., He, S., He, Y., Yang, Q., & Yang, G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s522929 · Cited by 5
Yazaki, K., Matsuyama, M., Satoh, H., Miyazaki, K., Arai, N., Ishii, Y., Endo, T., Kaburagi, T., Kawakami, T., Iijima, H., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04048-3 · Cited by 7
Bertolotto, M. B., de Totero, D., Giannoni, P., Barisione, E., Grosso, M., Nano, E., Fiocca, R., Pigozzi, S., Tedone, E., Valle, L., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70162 · Cited by 10
“10,11 While their role is currently limited to reducing the progression rate of ILDs, recent evidence is extending the applications of nintedanib to the prevention 12,13 and even treatment of lung cancers in patients with ILDs.”
Kim, B., Han, K., Park, J., Kim, B., Han, D., Chung, S. J., Kang, H. K., Kim, S., Park, M. S., Sohn, J. W., et al. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251406024 · Cited by 4
Wuyts, W. A., LANCASTER, L. H., Maher, T. M., Ryerson, C. J., Kreuter, M., Corte, T. J., Valenzuela, C., Barnes, C. N., Lefebvre, E. A., Cosgrove, G. P., et al. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002937 · Cited by 8
Self-citationImmunometabolism in Cardiac Remodeling: Mechanisms and Therapeutic Perspectives
Nazaruk, J., Bilnik, B., Niewiadomski, M., Pawlak, W., & Gajewski, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093906 · Cited by 7
“For example, pirfenidone and nintedanib have been shown to inhibit fibroblast activation and extracellular matrix deposition in both experimental studies and clinical trials [102,103].”
Perreault, A., Harper, K., Lebel, M., Charbonneau, M., Adam, D., Brochiero, E., Cantin, A. M., Leduc, M., Gagnon, L., & Dubois, C. M. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0037ma · Cited by 7
Chronic Respiratory Disease: COPD, IPF
Incalzi, R. A., & Fimognari, F. L. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_22 · Cited by 4
Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.
Çilli, A., & Üzer, F. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i3.14048 · Cited by 12
Gregor, J., Adir, Y., Šterclová, M., Moğulkoç, N., Kramer, M. R., Doubková, M., Plačková, M., Müller, V., Studnicka, M., Žůrková, M., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.12.002 · Cited by 5
Pennati, F., Belenkov, S., Buccardi, M., Ferrini, E., Sverzellati, N., Villetti, G., Aliverti, A., & Stellari, F. F. (2024) · iScience · doi:10.1016/j.isci.2024.109262 · Cited by 6
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D. A., Atwood, M., Samara, K. D., Kirchgässler, K.-U., & Maher, T. M. (2024) · ERJ Open Research · doi:10.1183/23120541.00666-2023 · Cited by 5
Pugashetti, J. V., Kim, J. S., Combs, M. P., Ma, S., Adegunsoye, A., Linderholm, A., Strek, M. E., Chen, C., Dilling, D. F., Whelan, T. P. M., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.03.018 · Cited by 4
Self-citationClinical utility, reproducibility, and radiologist acceptance of ILD-RADS
Elshetry, A. S. F., El-fawakry, R. M., Zaiton, F., et al. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111473 · Cited by 4
Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan
Bando, M., Chiba, H., Miyazaki, Y., & Suda, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.06.006 · Cited by 7
Innovations in Childhood Interstitial and Diffuse Lung Disease
Casey, A. M. H., Fiorino, E. K., & Wambach, J. A. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.04.002 · Cited by 4
Quality of life in idiopathic pulmonary fibrosis in Latin American countries
Aguilar‐Duran, H., Fernández, M., González-García, M., Rincón-Álvarez, E., Alberti, M. L., Caro, F. M., Tavera, E., Vásquez, E., Cortez, N., Salinas, M., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03506-2 · Cited by 6
Epidemiology of idiopathic pulmonary fibrosis in central and Western Pennsylvania
Linkov, F. Y., Chang, Y., Ramanan, H., Morgan, R. S., McTigue, K. M., Dimmock, A. E. F., Bascom, R., & Kass, D. J. (2025) · Respiratory Research · doi:10.1186/s12931-025-03164-2 · Cited by 4
Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5
Development of a Polidocanol-based Human In Vitro Model to Explore Airway Epithelial Repair
Chakraborty, A., Zöller, M., Sardogan, A., Klotz, M., Mastalerz, M., Marchi, H., Meixner, R., Hatz, R. A., Behr, J., Hilgendorff, A., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0117oc · Cited by 8
New Hydroxybenzoic Acid Salts of Nintedanib with Improved Aqueous Solubilities
Madhesiya, A., Maji, S., Panda, G., et al. (2025) · Crystal Growth & Design · doi:10.1021/acs.cgd.5c00219 · Cited by 4
Wang, R., Yang, F., Liu, Y., Peng, M., Yu, L., Hou, Q., Liu, Y., & Cheng, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1506518 · Cited by 5
Graham, C. S., Bisson, B., Shore, J. E., Pardy, E., Salisbury, F., LANCASTER, L. H., & Kulkarni, T. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03689-8 · Cited by 5
Yang, Z. H., Yao, Y., Chen, X., Madigan, V. J., Pu, S., Fan, X., Pu, J., & Bei, F. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102144 · Cited by 7
Rho kinase inhibitors: a patent review (2017–2023)
de Oliveira, D. R., Tolomeu, H. V., Fraga, C. A. M., & Lima, L. M. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2522735 · Cited by 5
Ito, K., Kato, S., Yasuda, N., Sawamura, S., Fukui, K., Iwasawa, T., Ogura, T., & Utsunomiya, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155329 · Cited by 4
“Pirfenidone and nintedanib, approved based on large-scale randomized trials such as ASCEND and INPULSIS, have demonstrated efficacy in slowing disease progression in idiopathic pulmonary fibrosis (IPF) and progressive fibrosing ILDs [22,23].”
Zhao, L., Liu, H., Yao, X., Ma, X., Liu, B., Li, B., Tong, H. H. Y., & Zhang, Q. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01521 · Cited by 4
Shared immunological pathways in rheumatoid arthritis-related interstitial lung disease
Xu, J., Li, C., Zhao, J., & Mu, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630729 · Cited by 6
P, Á. U. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.06.006 · Cited by 36
Jo, H. E., Corte, T. J., Wort, S. J., Eves, N. D., Piper, A. J., & Wainwright, C. E. (2016) · Respirology · doi:10.1111/resp.12749 · Cited by 5
Management and support of patients with fibrosing interstitial lung diseases
Barbera, T., Davila, L., & Patel, N. M. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000743332.64602.aa · Cited by 4
Investigation of effect of nintedanib in experimental uveitis model
Yıldırım, H., Balbaba, M., Erdağ, M., Dal, A., Canleblebici, M., İlhan, N., & Eröksüz, Y. (2021) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2021.2016804 · Cited by 4
Wang, R. T., Xu, J., Yan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998245 · Cited by 4
“NDNB is a tyrosine kinase inhibitor that selectively binds to VEGFRs, FGFRs, and PDGFRs and then inhibits the signals associated with proliferation, migration and transformation in fibroblasts (Richeldi et al., 2014; Guzy et al., 2017; Tepede and Yogaratnam, 2019).”
BackgroundThe road to hell is paved with good intentions: a look back at the PANTHER-IPF trial
Kam, M. L. W., Caliez, J., Nunès, H., & Gille, T. (2022) · Breathe · doi:10.1183/20734735.0074-2022 · Cited by 6
Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
Sakamoto, N., Kato, M., Ohni, T., et al. (2023) · Respirology Case Reports · doi:10.1002/rcr2.1085 · Cited by 4
Deng, C., Deng, G., & Zhu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1177329 · Cited by 4
“Recently, it has been approved for use in other chronic interstitial lung diseases with fibrotic phenotypes, because it has been found to significantly reduce the annual decline rate of forced vital capacity in multiple well-designed clinical trials (Richeldi et al., 2014; Flaherty et al., 2019; Wells et al., 2020).”
BackgroundAssassi, S., Tumuluri, S., & Levin, R. W. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/trcv91 · Cited by 6
Aoki, A., Hara, Y., Fujii, H., Murohashi, K., Nagasawa, R., Tagami, Y., Enomoto, T., Matsumoto, Y., Masuda, M., Watanabe, K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291489 · Cited by 5
“Nintedanib and pirfenidone are currently approved as AFT agents for IPF based on the results of large scale phase III clinical trials [8, 9].”
BackgroundCao, Z., Ramadan, A. M., Tai, A., Zetterberg, F. R., & Panjwani, N. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.11.018 · Cited by 6
Circulating biomarker analyses in a longitudinal cohort of patients with IPF
Ebert, C., Walsh, A. M., Sereda, L., Wilson, C. L., Schafer, P. H., Fischer, A., Zhao, L., Ramírez‐Valle, F., Gordon, D., & Schnapp, L. M. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00222.2023 · Cited by 5
Podolanczuk, A. J., & Aronson, K. I. (2024) · European Respiratory Journal · doi:10.1183/13993003.00067-2024 · Cited by 4
Tao, H., Lv, Q., Zhang, J., Chen, L., Yang, Y., & Sun, W. (2024) · Stem Cells International · doi:10.1155/2024/3429565 · Cited by 5
Maher, T. M., Tudor, V. A., Saunders, P., Zanghelini, F., Sampedro, C. G., Xydopoulos, G., Gibbons, M., Fletcher, S. V., Denton, C. P., Kokosi, M. A., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/lywq8541 · Cited by 8
Xu, F., Tong, Y., Yang, W., Cai, Y., Yu, M., Liu, L., & Meng, Q. (2024) · Respiratory Research · doi:10.1186/s12931-024-02738-w · Cited by 5
Nili, M., Epstein, A. J., Nunag, D., Olson, A. L., & Borah, B. J. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02929-7 · Cited by 6
Loss of ZNF451 mediates fibroblast activation and promotes lung fibrosis
Peng, H., Zhang, Y., Min, J., Tan, Y., & Liu, S. (2024) · Respiratory Research · doi:10.1186/s12931-024-02781-7 · Cited by 4
Identification of CFH and FHL2 as biomarkers for idiopathic pulmonary fibrosis
Liu, X., Yang, M., Li, J., Liu, H., Dong, Y., Zheng, J., & Huang, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1363643 · Cited by 6
“Only two recommended drugs (nintedanib and pirfenidone) that have been approved for IPF but can only delay the decline in lung function and cannot stop the progression of the disease (11, 12).”
BackgroundSöllner, J. F., Bentink, S., Heßlinger, C., Leonard, T. B., Neely, M. L., Patel, N. M., Schlange, T., Todd, J. L., Vinisko, R., Salisbury, M. L., et al. (2024) · Lung · doi:10.1007/s00408-024-00742-x · Cited by 4
Pathogenesis and Therapy of Hermansky–Pudlak Syndrome (HPS)-Associated Pulmonary Fibrosis
Hu, X. M., Wei, Z., Wu, Y., Zhao, M., Zhou, L., & Lin, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011270 · Cited by 8
“It is imperative to identify more targeted drugs and explore combination drug treatment to address the limitations of individual drug treatment to achieve the desired outcomes.”
BackgroundWhat Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Moua, T., Baqir, M., & Ryu, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216304 · Cited by 9
“While two antifibrotic medications (nintedanib and pirfenidone) [2,3] have been shown to slow disease progression and are currently in use, a significant need remains for more effective agents that may prevent loss of lung function and even reverse fibrosis.”
BackgroundFicolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1
Gao, P., Lu, Y., Tang, K., Wang, W., Wang, T., Zhu, Y., Zhao, J., & Mao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05894-1 · Cited by 7
Anti-Inflammatory Effects of Aptamin C in Pulmonary Fibrosis Induced by Bleomycin
Shin, S., Jo, H., Agura, T., Jeong, S., Ahn, H., Pang, S., Lee, J., Park, J.-H., Kim, Y., & Kang, J. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121577 · Cited by 4
Tekgöz, E., Çolak, S., Güneş, E. Ç., Öcal, N., Çınar, M., & Yılmaz, S. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03848-6 · Cited by 9
Hayakawa, T., Sekihara, K., Tajiri, T., Shibata, M., Fujisawa, T., Suda, T., Shiiya, N., & Funai, K. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.11.018 · Cited by 5
Qiu, W., Wang, Q., Zhang, Y., Cao, X., Zhao, L., Cao, L., Sun, Y., Yang, F. L., Guo, Y., Sui, Y., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102210 · Cited by 4
Beneficial Impact of Nutritional Therapy on Idiopathic Pulmonary Fibrosis
Yamakawa, H., Ohta, H., Sato, S., et al. (2025) · Cureus · doi:10.7759/cureus.78594 · Cited by 4
“In patients with IPF, treatment with nintedanib has not been associated with serious adverse events but has been linked to increased gastrointestinal events such as diarrhea, appetite loss, nausea, and weight loss [2,4].”
Nakamura, T., Jinta, T., Kitamura, A., Tanaka, M., So, C., Ro, S., Imai, R., Okafuji, K., Tomishima, Y., & Nishimura, N. (2025) · Cureus · doi:10.7759/cureus.78750 · Cited by 6
“Pirfenidone is associated more frequently with nausea and rash/photosensitivity, whereas diarrhea and nausea are more frequently reported with nintedanib [10,11].”
Çelik, M., Koca, M., Halıcı, Z., Tavacı, T., Halıcı, H., Özkaraca, M., Karaköy, Z., & Bayraktutan, Z. (2025) · The Protein Journal · doi:10.1007/s10930-024-10247-4 · Cited by 4
Telomeropathies in Interstitial Lung Disease and Lung Transplant Recipients
Southern, B. D., & Gadre, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051496 · Cited by 11
“There are currently two approved therapies for IPF (pirfenidone, nintedanib) [68,69] and one approved therapy for progressive pulmonary fibrosis (nintedanib) [70].”
Jordan, M., Schmidt, K., Fuchs, M., Just, A., Pfanne, A., Willmer, L., Neubert, L., Werlein, C., Zardo, P., Pich, A., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534989 · Cited by 6
Sakamoto, N., Okamoto, M., Tobino, K., Ichiyasu, H., Ichikado, K., Ishii, H., Hamada, N., Yatera, K., Miyazaki, T., Ishimoto, H., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.05.007 · Cited by 7
Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review
Czyżak, B., & Majewski, S. (2025) · Advances in respiratory medicine · doi:10.3390/arm93040031 · Cited by 9
Total Syntheses of Deuterated Drugs: A Comprehensive Review
Munir, R., Zahoor, A. F., Khan, S. G., Hussain, S. M., Noreen, R., Mansha, A., Hafeez, F., Irfan, A., & Ahmad, M. H. (2025) · Topics in Current Chemistry · doi:10.1007/s41061-025-00515-x · Cited by 6
Drug development for chronic lung disease ‐ Mission impossible?
Ask, K., & Kolb, M. R. J. (2014) · Respirology · doi:10.1111/resp.12445 · Cited by 4
Self-citationWhere do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
Collard, H. R. (2015) · European Respiratory Journal · doi:10.1183/09031936.00237114 · Cited by 4
Self-citationMaher, T. M., Piper, A. J., Song, Y., Restrepo, M. I., & Eves, N. D. (2015) · Respirology · doi:10.1111/resp.12532 · Cited by 4
Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient
Jones, M. G., Walsh, S. L. F., Jones, K. D., & Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00265-2016 · Cited by 4
Self-citationThe Keys to Making a Confident Diagnosis of IPF
Wadhwa, A., & Flaherty, K. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_5 · Cited by 4
Self-citationKocher, E., Rendon, K. J., Kesler, D. O., et al. (2016) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2016.0193 · Cited by 4
Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail
Wells, A. U., & Antoniou, K. M. (2017) · Respirology · doi:10.1111/resp.13182 · Cited by 4
Severe idiopathic pulmonary fibrosis: A clinical approach
Lipsi, R., Mazzola, D., Caminati, A., Elia, D., Lonati, C., & Harari, S. A. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.014 · Cited by 5
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Suárez-Cuartín, G., & Molina‐Molina, M. (2019) · Breathe · doi:10.1183/20734735.0016-2019 · Cited by 4
“Nevertheless, both nintedanib and pirfenidone treatments were approved by the US Food and Drug Administration for IPF, as they showed a significant effect on FVC decline when compared to placebo [2, 8, 9].”
BackgroundMethodResultInfluentialCreamer, A. W., & Barratt, S. L. (2019) · Breathe · doi:10.1183/20734735.0002-2019 · Cited by 4
“For idiopathic pulmonary fibrosis (IPF), the most common and fatal ILD, antifibrotic therapies (nintedanib [1] and pirfenidone [2]) have been shown to slow rate of progression, but the disease remains incurable.”
BackgroundMagnetic Resonance in Crohn Disease
Rimola, J., & Capozzi, N. (2019) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2019.08.004 · Cited by 4
Practice guidelines for interstitial lung diseases: Widening the reach
Montesi, S. B. (2020) · Lung India · doi:10.4103/lungindia.lungindia_487_20 · Cited by 4
Holland, A. E., Dowman, L., & Smallwood, N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202007-2775ed · Cited by 5
Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib
Bournia, V.-K., Distler, O., Kravvariti, E., Mitsikostas, D. D., & Sfikakis, P. P. (2020) · European Respiratory Journal · doi:10.1183/13993003.03021-2020 · Cited by 4
Fink, L., & Jonigk, D. D. (2021) · Der Pathologe · doi:10.1007/s00292-020-00894-6 · Cited by 4
Nakashima, K., Yanagihara, T., Ishida, S., Ogo, N., Egashira, A., Asoh, T., & Maeyama, T. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101385 · Cited by 4
Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis
Hosono, T., Bando, M., Mizushina, Y., Sata, M., Hagiwara, K., & Sugiyama, Y. (2021) · Experimental Lung Research · doi:10.1080/01902148.2021.1916650 · Cited by 4
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL
Bracco, E., Ali, M. S., Magnati, S., & Saglio, G. N. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97528 · Cited by 4
Camp, R. L., Smith, M. L., Larsen, B. T., Roden, A. C., Farver, C. F., Moreira, A. L., Attanoos, R. L., Pillappa, R., Sansano, I., Fabro, A. T., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01522-6 · Cited by 3
Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series
Kypreos, M. A., Barbera, T., Newton, C. A., Glazer, C. S., & Adams, T. N. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101562 · Cited by 5
Management of fibrotic hypersensitivity pneumonitis
Mullin, M. L. L., Churg, A., & Ryerson, C. J. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000904 · Cited by 5
Research Burden of Interstitial Lung Diseases in Turkey - RBILD.
Ayçiçek, O., Çetınkaya, E., Üçsular, F. D., Bayram, N. G., Şenyiğit, A., Aksel, N., Atilla, N., Sarıoğlu, N., Niksarlıoğlu, E. Y. Ö., Ilgazlı, A., et al. (2022) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v39i1.12269 · Cited by 5
Correlating SFTPC gene variants to interstitial lung disease in Egyptian children
Abdelmegeid, A. K., Refeat, M. M., Ashaat, E. A., El‐Kamah, G. Y., El-Saiedi, S. A., El-Falaki, M. M., Ruby, M. O. E., & Amr, K. S. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00399-0 · Cited by 4
Zlatanova, T., Arabadjiev, J. I., Kirova, G., & Nikova, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.907321 · Cited by 4
“Nintedanib is active for both lung adenocarcinoma (7) and IPF (6); thus, second-line treatment with 75 mg/m2 docetaxel by intravenous infusion on day 1 (as a switch maintenance therapy) plus 200 mg oral nintedanib twice daily on days 2–21 every 3 weeks were administered until unacceptable adverse events or disease pro…”
BackgroundCano-Jiménez, E., Ortíz, A. D. R., Villar, A., Rodríguez‐Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Respiratory Research · doi:10.1186/s12931-022-02154-y · Cited by 5
Manifestations pulmonaires des maladies héréditaires du métabolisme
Mauhin, W., Brassier, A., London, J., Subran, B., Zeggane, A., Besset, Q., Jammal, C. E., Montardi, C., Mellot, C., Strauss, C., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.09.002 · Cited by 4
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.